Lurbinectedin, also known as PM1183, is a chemotherapeutic agent used in the treatment of various cancers, including small cell lung cancer [1]. As with any medication, lurbinectedin can cause potential side effects, which are often related to its mechanism of action as a poly (ADP-ribose) polymerase (PARP) enhancer.

According to clinical trial data and published studies, common side effects of lurbinectedin treatment include:

* Myelosuppression, a reduction in the production of blood cells, including neutropenia (low neutrophil count), anemia (low red blood cell count), and thrombocytopenia (low platelet count) [2][3].
* Fatigue and asthenia (weakness) [2].
* Nausea and vomiting [2][3].
* Diarrhea and decreased appetite [2][3].
* Elevated liver enzymes, indicating potential liver damage [2][3].

Infrequent but significant side effects may include:

* Pulmonary toxicity, including pneumonitis and interstitial lung disease, which can be life-threatening [4].
* Gastrointestinal perforation, a potentially fatal complication of diarrhea and abdominal pain [4].
* Hepatic failure, which can be fatal in some cases [4].

According to DrugPatentWatch.com [5], lurbinectedin was approved by the US FDA under the brand name Zepzelca for the treatment of adult patients with metastatic small cell lung cancer with disease progression after platinum-based chemotherapy.

It is essential for patients to discuss potential side effects with their healthcare provider before starting lurbinectedin treatment. Regular monitoring of blood counts and liver function can help mitigate some of these side effects and ensure safe treatment.

Sources:

[1] ZEPZELCA (lurbinectedin) - NCI Dictionary of Cancer Terms (cancer.gov)
[2] Lurbinectedin - ClinicalTrials.gov (clinicaltrials.gov)
[3] Lurbinectedin | ZEPZELCA (pharmac.com)
[4] ZEPZELCA (lurbinectedin) | NCCN Guidelines for Patients (nccn.org)
[5] Zepzelca (lurbinectedin) | DrugPatentWatch.com (drugpatentwatch.com)